title: Impact of KIF6 Polymorphism rs20455 on Coronary Heart Disease Risk and Effectiveness of Statin Therapy in 100 Patients from Southern Iran.
abstract: BACKGROUND
  The purpose of this study was to investigate the association between Trp719Arg (rs20455) and Coronary Heart Disease (CHD), and also Coronary Heart Disease reduction in individuals with this SNP during statin therapy in southern Iran. It has been shown that rs20455, which could affect the function of kinesin protein, is associated with Coronary Heart Disease and could be an effective factor for patients who take statin therapy.
  
  
  METHODS
  Patients and control individuals were genotyped for rs20455 Single Nucleotide Polymorphism (SNP) using ARMS PCR (Amplification Refractory Mutation System Polymerase Chain Reaction) and RFLP (Restriction Fragment Length Polymorphism) analysis. The effect of kinesin family member 6 (KIF6) on statin therapy was also examined among patients who had a history of one or two heart attacks.
  
  
  RESULTS
  It was found that rs20455 had a significant association with Coronary Heart Disease (Odds Ratio [OR] 3.17, 95% Confidence Interval [CI] 1.68 to 5.98). In addition, statin therapy was more effective in rs20455 carriers than non-carriers, with 80% of the carriers showed positive response to this treatment.
  
  
  CONCLUSIONS
  Trp 719Arg have an effect on development of Coronary Heart Disease but it is very useful for statin therapy. Overall, individuals with this Single Nucleotide Polymorphism can take statin therapy to prevent the catastrophic consequences of Coronary Heart Disease.
authors.affiliation: Department of Biology, Payame Noor University, Tehran, Iran.
authors.forename: Leila
authors.initials: L
authors.lastname: Hamidizadeh
authors.affiliation: Department of Biology, Payame Noor University, Tehran, Iran.
authors.forename: Reza
authors.initials: R
authors.lastname: Haji Hosseini Baghdad Abadi
authors.affiliation: Department of Cardiology, Shiraz University of Medical Science, Shiraz, Iran.
authors.forename: Mohammad Ali
authors.initials: MA
authors.lastname: Babaee Baigi
authors.affiliation: Department of Medical Genetics, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Hassan
authors.initials: H
authors.lastname: Dastsooz
authors.affiliation: Fars Heart Central Hospital, Shiraz, Iran.
authors.forename: Ali
authors.initials: A
authors.lastname: Khazaei Nejhad
authors.affiliation: 3)Department of Medical Genetics, Shiraz University of Medical Sciences, Shiraz, Iran. 5)Department of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Majid
authors.initials: M
authors.lastname: Fardaei
mesh_terms: D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D002423:Cause of Death; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D005260:Female; D005838:Genotype; D006579:Heterozygote; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007492:Iran; D016547:Kinesins / Q000235:genetics*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; C526774:KIF6 protein, human; D016547:Kinesins